InflaRx

InflaRx ROA

The Return on Assets (ROA) of InflaRx (IFRX) as of Nov 20, 2026 is -82.65 %. In the previous year, Return on Assets (ROA) was -60.60 % — a change of 36.39% (lower).

ROA

-82.65 %

YoY

36.39%

Last updated:

In 2025, InflaRx's return on assets (ROA) was -82.65 %, a 36.39% increase from the -60.60 % ROA in the previous year.

The InflaRx ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-18.73 EUR
Jan 1, 2019
-43.80 EUR
Jan 1, 2020
-38.52 EUR
Jan 1, 2021
-36.46 EUR
Jan 1, 2022
-28.79 EUR
Jan 1, 2023
-35.49 EUR
Jan 1, 2024
-60.60 EUR
Jan 1, 2025
-82.65 EUR
The InflaRx ROA history
YEARROAYoY
-82.65 %+36.39%
-60.60 %+70.72%
-35.49 %+23.27%
-28.79 %-21.03%
-36.46 %-5.35%
-38.52 %-12.05%
-43.80 %+133.91%
-18.73 %-4.03%
-19.51 %-35.56%
-30.28 %-77.91%
-137.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InflaRx Stock analysis

What does InflaRx do? Inflarx NV is a biotech company that was founded in 2007 and is headquartered in Jena, Germany. The company's goal is to develop innovative therapies for patients suffering from severe inflammatory diseases. Inflarx focuses on the active ingredient IFX-1, which can be used for various diseases. The company collaborates closely with partners from the industry and science to advance the development of new therapies. The history of Inflarx began in 2007 when Dr. Niels C. Riedemann, the co-founder of the company, discovered IFX-1. IFX-1 is an antibody that can selectively inhibit inflammatory processes in the body. Riedemann recognized the potential of IFX-1 to form a new class of therapeutics and subsequently founded Inflarx. Initially, Inflarx focused on the development of IFX-1 for the treatment of lung inflammation. However, the company later recognized the potential of IFX-1 for other diseases, including autoimmune diseases and rare diseases. Today, the company specializes in the development and marketing of therapies for the treatment of inflammatory diseases in adults. Inflarx's business model is based on the development and marketing of therapies using IFX-1. The company collaborates closely with partners from the pharmaceutical industry and science to develop new therapies. Inflarx has filed several patents for IFX-1 and has exclusive rights to its use in certain diseases. The company operates in several divisions. The "Lung Inflammatory Diseases" division focuses on the development of therapies for the treatment of lung inflammation. The "Autoimmune Diseases" division includes the development of therapies for the treatment of autoimmune diseases such as rheumatoid arthritis and Crohn's disease. The "Rare Diseases" division focuses on the development of therapies for the treatment of rare diseases where IFX-1 can be utilized. Currently, Inflarx does not offer any products on the market. However, the company is working on the development of therapies for the treatment of inflammatory diseases in adults. IFX-1 is currently in various stages of clinical development and is being tested for different indications. Inflarx has received promising data from clinical trials and plans to bring IFX-1 to the market in the future. In summary, Inflarx NV is a biotech company specializing in the development of therapies for the treatment of inflammatory diseases. The company discovered IFX-1 as an active ingredient and continues to develop its products based on it. Inflarx collaborates closely with partners from the pharmaceutical industry and science to develop new therapies and specializes in various divisions. Although Inflarx currently does not have any products on the market, the company has received promising data from clinical trials and plans to enter the market with IFX-1 in the future. InflaRx is one of the most popular companies on Eulerpool.

ROA Details

Understanding InflaRx's Return on Assets (ROA)

InflaRx's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing InflaRx's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider InflaRx's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in InflaRx’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about InflaRx stock

Return on Assets (ROA) of InflaRx is -82.65 % in 2025.

Return on Assets (ROA) of InflaRx changed from -60.60 % to -82.65 %, representing a 36.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) InflaRx since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s InflaRx with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — InflaRx

All Key Metrics — InflaRx